Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
1.320
-0.020 (-1.49%)
At close: Sep 26, 2025, 4:00 PM EDT
1.358
+0.038 (2.89%)
After-hours: Sep 26, 2025, 5:19 PM EDT
Scinai Immunotherapeutics Employees
Scinai Immunotherapeutics had 31 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
31
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$37,000
Profits / Employee
$11,194
Market Cap
2.00M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SCNI News
- 25 days ago - Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PRNewsWire
- 2 months ago - Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - PRNewsWire
- 3 months ago - Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - PRNewsWire
- 4 months ago - Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PRNewsWire
- 4 months ago - Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - PRNewsWire
- 5 months ago - Scinai Announces Annual Financial Results for 2024 - PRNewsWire
- 5 months ago - Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases - PRNewsWire
- 6 months ago - Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions - PRNewsWire